Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...

risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...